Green tea for ovarian cancer prevention and treatment: A systematic review of the in vitro, in vivo and epidemiological studies

被引:35
作者
Trudel, Dominique [1 ,2 ]
Labbe, David P. [3 ,4 ]
Bairati, Isabelle [2 ]
Fradet, Vincent [2 ,5 ]
Bazinet, Laurent [5 ]
Tetu, Bernard [2 ,6 ]
机构
[1] Toronto Gen Hosp, Univ Hlth Network, Dept Pathol Appl Mol Oncol, Toronto, ON M5G 2C4, Canada
[2] Univ Laval, Canc Res Ctr, Hotel Dieu de Quebec, Univ Hosp Ctr CHUQ, Quebec City, PQ G1R 2J6, Canada
[3] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ H3A 1A3, Canada
[4] McGill Univ, Div Expt Med, Dept Med, Montreal, PQ H3A 1A3, Canada
[5] Univ Laval, Dept Food Sci & Nutr, Inst Nutraceut & Funct Foods INAF, Quebec City, PQ G1V 0A6, Canada
[6] Univ Laval, Anat Pathol & Cytol Dept, Hop St Sacrement, CHA, Quebec City, PQ G1S 4L8, Canada
关键词
Epithelial ovarian cancer; Green tea; Camellia sinensis; Epigallocatechin gallate (EGCG); Human; Meta-analysis; CELL-LINES; BLACK TEA; POLYPHENOL EPIGALLOCATECHIN-3-GALLATE; GLUTAMATE TRANSPORTER; PROSPECTIVE COHORT; ANTITUMOR-ACTIVITY; FLAVONOID INTAKE; COFFEE-DRINKING; ENDOTHELIN AXIS; PHASE-I;
D O I
10.1016/j.ygyno.2012.04.048
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. This systematic review was conducted to examine the effects of green tea or green tea components on the prevention and progression of epithelial ovarian cancer. Methods. Using Medline, EMBASE and SciVerse (last researched: July 2011), we retrieved 22 articles including 5 epidemiological studies. Results. In epithelial ovarian cancer cell lines, green tea and green tea components have been shown to downregulate the expression of proteins involved in inflammation, cell signalization, cell motility and angiogenesis. Green tea and green tea components would induce apoptosis and could potentiate the effects of cisplatin, a chemotherapeutic agent. In human observational studies, significant associations between green tea intake and both decreased ovarian cancer occurrence and better prognosis were reported. Conclusions. Available literature suggests potential molecular targets for green tea in ovarian cancer treatment and also provides data supporting the clinical evaluation of the role of green tea or green tea components in ovarian cancer prevention and treatment. (c) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:491 / 498
页数:8
相关论文
共 75 条
[1]   The endothelin axis in cancer [J].
Bagnato, Anna ;
Rosano, Laura .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2008, 40 (08) :1443-1451
[2]   Consumption of black tea or coffee and risk of ovarian cancer [J].
Baker, J. A. ;
Boakye, K. ;
McCann, S. E. ;
Beehler, G. P. ;
Rodabaugh, K. J. ;
Villella, J. A. ;
Moysich, K. B. .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2007, 17 (01) :50-54
[3]   The chemistry of tea flavonoids [J].
Balentine, DA ;
Wiseman, SA ;
Bouwens, LCM .
CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, 1997, 37 (08) :693-704
[4]   Endothelin receptor antagonism and cancer [J].
Bhalla, A. ;
Haque, S. ;
Taylor, I. ;
Winslet, M. ;
Loizidou, M. .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2009, 39 :74-77
[5]   Green and black tea in relation to gynecologic cancers [J].
Butler, Lesley M. ;
Wu, Anna H. .
MOLECULAR NUTRITION & FOOD RESEARCH, 2011, 55 (06) :931-940
[6]  
BYERS T, 1983, JNCI-J NATL CANCER I, V71, P681
[7]   Epigallocatechin-3-gallate delivers hydrogen peroxide to induce death of ovarian cancer cells and enhances their cisplatin susceptibility [J].
Chan, MM ;
Soprano, KJ ;
Weinstein, K ;
Fong, D .
JOURNAL OF CELLULAR PHYSIOLOGY, 2006, 207 (02) :389-396
[8]   Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals [J].
Chow, HHS ;
Hakim, IA ;
Vining, DR ;
Crowel, JA ;
Ranger-Moore, J ;
Chew, WM ;
Celaya, CA ;
Rodney, SR ;
Hara, Y ;
Alberts, DS .
CLINICAL CANCER RESEARCH, 2005, 11 (12) :4627-4633
[9]   INFLUENCE OF CATECHINS AND THEAFLAVINS ON THE ASTRINGENT TASTE OF BLACK TEA BREWS [J].
DING, Z ;
KUHR, S ;
ENGELHARDT, UH .
ZEITSCHRIFT FUR LEBENSMITTEL-UNTERSUCHUNG UND-FORSCHUNG, 1992, 195 (02) :108-111
[10]   2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004) [J].
du Bois, A ;
Quinn, M ;
Thigpen, T ;
Vermorken, J ;
Avall-Lundqvist, E ;
Bookman, M ;
Bowtell, D ;
Brady, M ;
Casado, A ;
Cervantes, A ;
Eisenhauer, E ;
Friedlaender, M ;
Fujiwara, K ;
Grenman, S ;
Guastalla, JP ;
Harper, P ;
Hogberg, T ;
Kaye, S ;
Kitchener, H ;
Kristensen, G ;
Mannel, R ;
Meier, W ;
Miller, B ;
Neijt, JP ;
Oza, A ;
Ozols, R ;
Parmar, M ;
Pecorelli, S ;
Pfisterer, J ;
Poveda, A ;
Provencher, D ;
Pujade-Lauraine, E ;
Randall, M ;
Rochon, J ;
Rustin, G ;
Sagae, S ;
Stehman, F ;
Stuart, G ;
Trimble, E ;
Vasey, P ;
Vergote, I ;
Verheijen, R ;
Wagner, U .
ANNALS OF ONCOLOGY, 2005, 16 :7-12